Darlene Dobkowski, MA

This particular designation may expedite the process of approving Xpovio for the treatment of patients with myelofibrosis to address an unmet medical need.

Patients with Medicaid or no insurance may have worse survival outcomes compared with Medicare or private insurance in those with metastatic renal cell carcinoma.

Palliative care can benefit patients with advanced cancer by integrating advanced care planning, pain and symptom management and counseling, among other aspects.

Adolescents and young adults undergoing VEGF treatment for nonmetastatic, high-risk renal cell carcinoma may still experience heart-related conditions like left ventricular systolic dysfunction and high blood pressure.

Immunotherapy with Opdivo plus cisplatin-based chemotherapy improved overall survival and progression-free survival in patients with unresectable or metastatic urothelial carcinoma.

Fruquintinib improved overall survival compared with placebo in patients with refractory metastatic colorectal cancer.

Reblozyl treatment in patients with anemia from lower-risk myelodysplastic syndromes achieved a greater independence from red blood cell transfusions compared with treatment with epoetin alfa.

If the FDA approves zolbetuximab, this would mark the first CLDN18.2-targeting monoclonal antibody to treat patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Fit patients with chronic lymphocytic leukemia treated with Venclexta and Gazyva, regardless of the use of Imbruvica, experienced improvements in progression-free survival and were more likely to obtain undetectable minimal residual disease.

Patients with advanced cancers who live in states that expanded Medicaid were more likely to receive early palliative care, although utilization remains low in the U.S.

Artificial intelligence was used to develop a predictive biomarker to identify patients with intermediate-risk prostate cancer who would benefit from adding androgen deprivation therapy to radiotherapy.

Patients 65 years and older with NSCLC and undergoing treatment with immunotherapy, chemotherapy and/or targeted therapy were more likely to have worse survival outcomes and declines in activity of daily living.

Findings from a study conducted in women with a history of breast cancer demonstrated that treatment with donepezil, which is typically used to treat symptoms of Alzheimer’s disease and dementia, did not improve cognitive impairment, or “chemo brain.”

Cryotherapy may reduce the occurrence of peripheral neuropathy in patients with breast cancer undergoing chemotherapy with paclitaxel and nab-paclitaxel, according to recent findings from an analysis.

Patients 60 years and older with gastrointestinal cancers who reported inadequate emotional support were more likely to have poorer physical and mental quality of life, although no effect was observed in overall survival.

Patients with unresectable hepatocellular carcinoma, a type of liver cancer, obtained a survival benefit over four years of follow-up with a treatment regimen of Imfinzi and Imjudo.

Treatment with a CAR-M cell therapy plus Keytruda is being assessed in a phase 1 study in patients with HER2-overexpressed tumors.

Findings from a recent study demonstrated that exposure to Agent Orange increased the risk for bladder cancer but did not affect the disease’s aggressiveness.

Patients 65 years and older treated with Venclexta, Imbruvica and Gazyva for CLL had similar rates of progression-free survival compared with those treated with Imbruvica and Gazyva.

Musician Andrew McMahon has made it his mission to spread the message of community and seeking mental health care like therapy for adolescents and young adults with cancer.

The combination of Talzenna and Xtandi was approved for the treatment of adults with HRR gene-mutated metastatic castration-resistant prostate cancer.

Watch Dr. John O. Mascarenhas, from Icahn School of Medicine, discuss novel therapies in myelofibrosis during the CURE® Educated Patient® MPN Summit.

Watch Dr. Rami Komrokji, from Moffitt Cancer Center, discuss risk stratification and management of myelofibrosis during the CURE® Educated Patient® MPN Summit.

Columvi is the first bispecific antibody that can be administered to patients with relapsed or refractory diffuse large B-cell lymphoma for a defined period of time.

The application for capivasertib plus Faslodex in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer has also been granted priority review, meaning that the FDA has six months to make a decision.

Treating patients with metastatic castration-resistant prostate cancer with radium-223 also allowed patients to receive subsequent therapies such as chemotherapy.

Lynparza plus abiraterone was approved by the FDA for the treatment of patients with deleterious or suspected BRCA-mutated metastatic castration-resistant prostate cancer.

The agency accepted a New Drug Application for repotrectinib, a TKI for the treatment of patients with locally advanced or metastatic non-small cell lung cancer.

Some symptoms of myeloproliferative neoplasms are “pretty broad,” highlighting the importance of open communication with cancer teams to manage the symptoms and improve quality of life.

Women with hormone receptor-positive breast cancer who temporarily interrupted endocrine therapy for pregnancy had a similar recurrence rate to those from a control group, but one expert said that stopping therapy for a short time is still an important decision.